NCT03054519View on ClinicalTrials.gov

Improve PAD PERformance With METformin

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

May 23, 2017

Primary Completion Date

August 20, 2025

Study Completion Date

November 30, 2025

Conditions
Peripheral Artery Disease
Interventions
DRUG

Metformin

Participants will be prescribed up to 2,000 mgs daily of metformin

DRUG

Placebo

Placebo pills will appear identical to the metformin to maintain blinding of participants and investigators.

Trial Locations (5)

32610

University of Florida, Gainesville

60611

Northwestern University, Chicago

60637

University of Chicago, Chicago

70112

Tulane University, New Orleans

70121

Ochsner Medical Center, New Orleans

All Listed Sponsors
lead

Northwestern University

OTHER